A2A and A3 receptors mediate the adenosine-induced relaxation in spontaneously active possum duodenum in vitro.
1. The aim of this study was to define the P1 purinergic receptors that regulate spontaneous or adenosine-induced duodenal motor activity. 2. Spontaneous contractile activity was recorded isometrically from possum longitudinal duodenal muscle strips. Adenosine (0.5 micro M-1 mM) was administered noncumulatively and repeated after pretreatment with a P1 antagonist or tetrodotoxin (TTX, 1 micro M), (n=4-7). Antagonists used were: A(1), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 10 nM); A(2A), 8-(3-chlorostyryl)caffeine (CSC, 10 micro M); A(2B), 3-isobutyl-8-pyrrolidinoxanthine (IPDX, 10 micro M); A(3), 9-chloro-2-(2-furanyl)-5-[(phenylacetyl) amino][1,2,4]-triazolo(1,5-c)quinazoline (MRS1220, 10 micro M). Changes in activity are expressed as percentage of baseline. Statistical analysis utilised nonparametric tests. 3. Adenosine (n=34) induced a long-lasting, concentration-dependent decrease in activity by 55.6+/-3.2% area under curve (AUC), 47.3+/-4.0% contraction amplitude, 31.6+/-3.6% basal tension and 10.4+/-1.7% contraction frequency (all P<0.001). The adenosine-induced decrease in contraction amplitude was blocked by CSC (P<0.01) or inhibited by MRS1220 (P<0.03) pretreatment, but not modified by TTX, DPCPX or IPDX pretreatment. 4. Adenosine antagonists modified spontaneous contractile activity. Pretreatment with DPCPX or CSC increased basal tension, whereas IPDX or MRS1220 pretreatment decreased contractile activity. 5. In conclusion, exogenous adenosine reduced duodenal longitudinal motor activity via A(2A) and A(3) receptors. Our findings suggest that endogenous purines may modulate spontaneous duodenal motor activity.
Woods
C M
CM
Department of General and Digestive Surgery, Centre for Neuroscience, Flinders Medical Centre, Flinders University of South Australia, PO Box 2100, Adelaide 5001, Australia. charmaine.woods@flinders.edu.au
Toouli
J
J
Saccone
G T P
GT
D000241:Adenosine / Q000378:metabolism*; D000818:Animals; D004386:Duodenum / Q000187:drug effects*; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009893:Opossums; D058915:Purinergic P1 Receptor Antagonists; D011760:Pyrrolidinones / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology*; D013997:Time Factors; D014230:Triazoles / Q000494:pharmacology*; D014970:Xanthines / Q000494:pharmacology*
C439368:3-isobutyl-8-pyrrolidinoxanthine; C110041:9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline; D058915:Purinergic P1 Receptor Antagonists; D011760:Pyrrolidinones; D011799:Quinazolines; D018047:Receptors, Purinergic P1; D014230:Triazoles; D014970:Xanthines; D013779:Tetrodotoxin; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000241:Adenosine